NCI Board of Scientific Advisors rejects the Institute’s $89 million proteomics research plan.
Proof of principle needed before launching “big science” program, advisors say.
Also in this 12-page issue: NCI’s Lance Liotta and FDA’s Emanuel Petricoin to move to George Mason University.
Zvi Fuks of Memorial Sloan-Kettering arrested and charged with securities fraud related to sale of ImClone stock.
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
